NCT05852717View on ClinicalTrials.gov

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2028

Conditions
Large Cell Lymphoma, DiffuseRelapsed CancerRefractory Cancer
Interventions
PROCEDURE

AutoSCT OR CAR T-cell Therapy

Autologous stem cell transplant (AutoSCT) or CAR T-cell therapy will be performed after Cycle 3 of receiving epcoritamab and GDP

DRUG

GDP

Gemcitabine Cisplatin Dexamethasone

DRUG

Epcoritamab

Epcoritamab

Trial Locations (4)

22908

RECRUITING

University of Virginia Health System, Charlottesville

46202

RECRUITING

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis

48201

RECRUITING

Karmanos Cancer Center (Wayne State University), Detroit

75390

RECRUITING

University of Texas Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Genmab
All Listed Sponsors
collaborator

Genmab

INDUSTRY

lead

Dipenkumar Modi

OTHER

NCT05852717 - Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | Biotech Hunter | Biotech Hunter